Evidence map›Paper›PMID 34998527›Full record

ArticleInternational journal of radiation oncology, biology, physics2022

Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead.

Henning Willers, Mechthild Krause, Corinne Faivre-Finn, Anthony J Chalmers

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Henning WillersMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: hwillers@mgh.harvard.edu.
Mechthild KrauseOncoRay - National Center for Radiation Research in Oncology and Dept. of Radiotherapy & Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden; Helmholtz-Zentrum Dresden - Rossendorf, German Cancer Consortium (DKTK), Partner Site Dresden; National Center for Tumor Diseases (NCT), Partner Site Dresden; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Corinne Faivre-FinnUniversity of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, United Kingdom.
Anthony J ChalmersInstitute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Funding

High-Throughput Screening and Validation of Molecular Targeted ChemoradiosensitizersU01CA220714 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HATA, AARON N, WILLERS, HENNING · 2018 to 2022
$3.1M
Cancer Research UK 17870Cancer Research UK 20546Cancer Research UK 28803NCI NIH HHS U01 CA220714
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Poly(ADP-ribose) Polymerase InhibitorsHumansPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID34998527
PMCPMC9074417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.